
1/Capstan Therapeutics which develops in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles-tLNP, has announced the successful closing of a $175M oversubscribed Series B financing aimed to advance its leading in vivo CAR-T program - CPTX2309. $XBI














